Abu Dhabi administers pioneering breast cancer drug to patient in world first (opens original article in a new tab)

Abu Dhabi's Burjeel Cancer Institute became the first to administer Camizestrant, a new breast cancer drug, to a patient with ESR1 mutation, marking a medical milestone.

• Abu Dhabi's Burjeel Cancer Institute administered Camizestrant, a new breast cancer drug, to a patient with ESR1 gene mutation.
• The drug was approved by Emirates Drugs Establishment after clinical trials and shown to reduce disease progression risk by 56% in patients with ESR1 mutation.
• Camizestrant is part of a precision oncology model using ctDNA monitoring for early detection of treatment resistance.